NEW YORK (GenomeWeb News) – Quanterix today said that it has received an investment from In-Q-Tel, an independent strategic investment firm that identifies technologies that support the missions of the US intelligence community, to support further development of its Single Molecule Array (SiMoA) technology.
Cambridge, Mass.-based Quanterix said that it would work with In-Q-Tel to develop its platform to enable simultaneous measurement of both nucleic acids and proteins for the detection of pathogens. It said that SiMoA will "facilitate the direct and non-amplified detection of pathogens to obtain a level of sensitivity that could previously only be achieved with amplification methods."
Quanterix did not disclose the amount of the investment by In-Q-Tel.
"The ability to accurately detect the presence of low abundance molecules makes Quanterix technology a critical addition to our strategic investment portfolio," Syd Ulvick, VP of physical and biological technologies practice at In-Q-Tel, said in a statement.